Labetalol steady-state pharmacokinetics in hypertensive patients.
Abstract ::: 1 During chronic treatment of hypertensive patients observed mean steady-state plasma labetalol levels in ten patients were consistently and significantly higher than predicted from initial acute pharmacokinetic analysis. ::: ::: 2 Mean steady-state levels varied from 36 to 183 ng/ml on a chronic dose of 200 mg twice daily. ::: ::: 3 Patients with lower steady-state levels on a fixed dose of labetalol usually required higher maintenance doses to control blood pressure.
An experimental study on wavelength stability of laser diode(LD) was presented,which was based on the wavelength-temperature relationship.An ultrahigh wavelength stabilization was designed by adopting a new integrated semiconductor LD module with a wavelength-monitor.There have no use for other additional devices in this design.The wavelength drift is compensated through temperature,and the wavelength real time lock is realized.Enhancing the bias current and changing the setting temperature were employed to test the characteristic of the system.Experiment shows that the wavelength stability is less than or equal 2 pm,and that the wavelength control precision is less than or equal ±2 pm.